Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Proposed Sale · 144

Pharvaris N.V.

PHVSNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Sep 9, 2026Accepted Sep 9, 2026, 4:16 PM EDTFiling CIK 1830487Accession 0001950047-26-009236
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
PHARVARIS N.V.
Issuer CIK
0001830487
SEC file number
001-40010
Phone
31 (0)71 2036 410
Person for whose account securities are to be sold
ROBERT R. GLASSMAN
Relationships to issuer
Director
Street
Emmy Noetherweg 2
City
Leiden
State / country code
P7
Postal code
2333 BK

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Common8,000300,396.0070,204,50609/09/2026NASDAQMorgan Stanley Smith Barney LLC Executive Financial Services

Broker / market maker — proposed row 1, entry 1

Name
Morgan Stanley Smith Barney LLC Executive Financial Services
Street
1 New York Plaza
Street (continued)
8th Floor
City
New York
State / country code
NY
Postal code
10004

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
Common09/09/2026Stock Option ExerciseIssuer8,000N09/09/2026Cash

Prior-sale reporting

Nothing to report for the preceding three months
Y

Notice signature

Notice date
09/09/2026
Signed
/s/ Robert Howard Glassman

Company context

Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. For more information, visit https://pharvaris.com/.

Current securities

Recent company filings

  1. SCHEDULE 13G/A - filed by VIKING GLOBAL INVESTORS LP regarding Pharvaris N.V.Nov 16, 2026
  2. SCHEDULE 13G - filed by WELLINGTON MANAGEMENT GROUP LLP regarding Pharvaris N.V.Nov 16, 2026
  3. SCHEDULE 13G/A - filed by GENERAL ATLANTIC, L.P. regarding Pharvaris N.V.Nov 13, 2026
  4. 6-K filingNov 12, 2026
  5. 144 filingSep 23, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.